-
1 Comment
From a valuation standpoint, the stock is 95.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.1.
Based on the above factors, Viridian Therapeutics, Inc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US92790C1045 |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Target Price | 38.5 |
| Beta | 0.62 |
| Market Cap | 1B |
| Dividend Yield | None |
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VRDN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
